Fruquintinib has shown clinical benefit in patients with metastatic colorectal cancer, regardless of where the cancer has spread in the body. The treatment's efficacy has been supported by real-world data in patients who have previously received treatment for the disease. However, the specifics of its use and benefits in relation to other treatments, such as anlotinib and sintilimab, are still being explored.